Vitamin D Research

back to research menu

Pharmacology

• What is new in vitamin D: 2006–2007.Curr Opin Rheumatol. 2007 Jul;19(4):383–8.
• Phenobarbital suppresses vitamin D3 25‑hydroxylase expression: a potential new mechanism for drug‑induced osteomalacia.Biochem Biophys Res Commun. 2007 Jun 8;357(3):603–7. Epub 2007 Apr 9.
• Efficacy of daily and monthly high‑dose calciferol in vitamin D‑deficient nulliparous and lactating women.Am J Clin Nutr. 2007 Jun;85(6):1565–71.
• Effect of 2‑Methylene‑19‑nor‑(20S)‑1alpha‑Hydroxy‑ Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism.J Bone Miner Res. 2007 May;22(5):686–94.
• Effects of atorvastatin on vitamin d levels in patients with acute ischemic heart disease.Am J Cardiol. 2007 Apr 1;99(7):903–5. Epub 2007 Feb 8.
• Successful treatment of refractory warts with topical vitamin D(3) derivative (maxacalcitol, 1alpha, 25‑dihydroxy‑22‑oxacalcitriol) in 17 patients.J Dermatol. 2007 Apr;34 (4):264–6.
• Vitamin D analogs for secondary hyperparathyroidism: What does the future hold?J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):578–83. Epub 2006 Dec 27.
• Structure‑activity relationships of 19‑norvitamin D analogs having a fluoroethylidene group at the C‑2 position.Bioorg Med Chem. 2007 Feb 1;15(3):1475–82. Epub 2006 Nov 3.
• Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–44. Review.
• New 19‑nor‑(20S)‑1alpha,25‑dihydroxyvitamin D(3) analogs strongly stimulate osteoclast formation both in vivo and in vitro.Bone. 2007 Feb;40(2):293–304. Epub 2006 Oct 25.
• ED‑71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation.Bone. 2007 Feb;40(2):281–292. Epub 2006 Oct 16.
• Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL‑628 (elocalcitol).J Steroid Biochem Mol Biol. 2007 Jan 19;
• Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC‑Trial).Rheumatol Int. 2007 Jan 11;.
• Difluoromethyl analogs of the natural hormone 1alpha,25‑dihydroxyvitamin D(3): Design, synthesis, and preliminary biological evaluation.J Steroid Biochem Mol Biol. 2007 Jan 9;.
• Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.Am J Nephrol. 2007;27(1):36–43. Epub 2007 Jan 11.
• Synthesis and evaluation of a 3‑position diastereomer of 1alpha,25‑dihydroxy‑2beta‑(3‑hydroxypropoxy)vitamin D(3) (ED‑71).Bioorg Med Chem. 2006 Dec 1;14(23):8050–6.
• Phase I study of weekly DN‑101, a new formulation of calcitriol, in patients with cancer.Cancer Chemother Pharmacol. 2006 Oct 26;
• Comparison of the efficacy of calcipotriol and maxacalcitol in combination with narrow‑band ultraviolet B therapy for the treatment of psoriasis vulgaris.Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):262–4.
• Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.Pediatr Nephrol. 2006 Oct;21(10):1434–9. Epub 2006 Aug 10.
• Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N.AIDS. 2006 Sep 11;20(14):1906–1907.
• Antiepileptic drugs and bone metabolism.Nutr Metab (Lond). 2006 Sep 6;3(1):36
• Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.Mov Disord. 2006 Jul;21(7):924–9.
• Synthesis of putative metabolites of 1alpha,25‑dihydroxy‑2beta‑(3‑hydroxy propoxy)vitamin D(3) (ED‑71).Steroids. 2006 Jul;71(7):529–40. Epub 2006 Apr 25.
• Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.J Pharmacol Exp Ther. 2006 Jul;318(1):90–8. Epub 2006 Apr 7.
• Vitamin D receptor is a novel drug target for ovarian cancer treatment.Curr Cancer Drug Targets. 2006 May;6(3):229–44. Review.
• New 2‑alkylidene 1alpha,25‑dihydroxy‑19‑norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2‑(3'‑alkoxypropylidene) and 2‑(3'‑hydroxypropylidene) derivatives.J Med Chem. 2006 May 18;49(10):2909–20.
• Phase II trial of high‑dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‑independent prostate cancer.Cancer. 2006 May 15;106(10):2136–42.
• Practical synthesis and evaluation of the biological activities of 1alpha,25‑dihydroxy vitamin D3 antagonists, 1alpha,25‑dihydroxy vitamin D3‑26,23‑lactams. Designed on the basis of the helix 12‑folding inhibition hypothesis.J Med Chem. 2006 Apr 20;49(8):2398–406.
• Oral treatment with a vitamin D3 analogue (BXL628) has anti‑inflammatory effects in rodent model of interstitial cystitis.BJU International Volume 97 Page 617—March 2006
• Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.Rheumatol Int. 2006 Mar;26(5):445–53. Epub 2005 Nov 10.
• Pharmacological treatment to augment hole board habituation in prenatal Vitamin D‑deficient rats.Behav Brain Res. 2006 Jan 6;166(1):177–83. Epub 2005 Sep 26.
• Vitamin D analogs as anti‑carcinogenic agents.Anticancer Agents Med Chem. 2006 Jan;6(1):53–71. Review.
• New horizons of ED‑71 (vitamin D analog)Clin Calcium. 2006 Jan;16(1):131–5. In Japanese.
• Phase I/II study of 19‑nor‑1alpha‑25‑dihydroxyvitamin D2 (paricalcitol) in advanced, androgen‑insensitive prostate cancer.Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8680–5.
• Pharmacokinetics and tolerability of a single dose of DN‑101, a new formulation of calcitriol, in patients with cancer.Clin Cancer Res. 2005 Nov 1;11(21):7794–9.
• Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?Kidney Int. 2005 Nov;68(5):1973–81. Review.
• Immunoregulation by 1,25‑dihydroxyvitamin D3: basic concepts.J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):93–101. Epub 2005 Jul 19. Review.
• Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs.J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):111–20. Epub 2005 Sep 8.
• Inhibitory effect of 22‑oxa‑1,25‑dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines.J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):173–7. Epub 2005 Jul 20.
• Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs.J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):137–43. Epub 2005 Jul 20.
• Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation‑induced osteoporosis.J Rheumatol Suppl. 2005 Sep;76:33–40.
• Alfacalcidol versus plain vitamin D in inflammation induced bone loss.J Rheumatol Suppl. 2005 Sep;76:26–32. Review.
• High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.J Urol. 2005 Sep;174(3):888–92.
• The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.J Musculoskelet Neuronal Interact. 2005 Jul–Sep;5(3):273–84. Review.
• The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.Arch Intern Med. 2005 Aug 8–22;165(15):1737–42.
• Antioxidative effect of vitamin D3 on zinc‑induced oxidative stress in CNS.Ann N Y Acad Sci. 2005 Aug;1053:319–29.
• Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post‑menopausal osteoporosis.Cochrane Database Syst Rev. 2005 Jul 20;(3):CD000227. Review.
• Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis‑related fractures: a comparative meta‑analysis.Calcif Tissue Int. 2005 Mar;76(3):176–86. Epub 2005 Feb 7.
• Lack of effect of calcium intake on the 25‑hydroxyvitamin d response to oral vitamin D3.J Clin Endocrinol Metab. 2005 Feb;90(2):707–11. Epub 2004 Nov 23.
• Altered pharmacokinetics of 1alpha,25‑dihydroxyvitamin D3 and 25‑hydroxyvitamin D3 in the blood and tissues of the 25‑hydroxyvitamin D‑24‑hydroxylase (Cyp24a1) null mouse.Endocrinology. 2005 Feb;146(2):825–34. Epub 2004 Oct 21.
• Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease.Bone. 2005 Jan;36(1):61–8. Epub 2004 Nov 24.
• A pilot study of oral calcitriol (1,25‑dihydroxyvitamin D3) for relapsing‑remitting multiple sclerosis.JNNP 2005;76:1294–1296.
• Inhibition of proliferation and induction of apoptosis by 25‑hydroxyvitamin D3‑3beta‑(2)‑Bromoacetate, a nontoxic and vitamin D receptor‑alkylating analog of 25‑hydroxyvitamin D3 in prostate cancer cells.Clin Cancer Res. 2004 Dec 1;10(23):8018–27.
• Toxicity and antineoplastic effect of (24R)‑1,24‑dihydroxyvitamin D3 (PRI‑2191).Steroids. 2004 Sep;69(10):629–35.
• Vitamin D2 Is Much Less Effective than Vitamin D3 in HumansJournal of Clinical Endocrinology & Metabolism 2004 Aug Vol. 89, No. 11 5387–5391
• Zinc–induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3.Free Radic Biol Med. 2003 Jun 1;34(11):1416–25.
• New vitamin D analogs.Kidney Int Suppl. 2003 Jun;(85):S83–7. Review.
• Rationale for active vitamin D and analogs in the treatment of osteoporosis.J Cell Biochem. 2003 Feb 1;88(2):381–6. Review.
• Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.Recent Results Cancer Res. 2003;164:273–88.
• Pharmacokinetics of high‑dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.Clin Pharmacol Ther. 2002 Dec;72(6):648–59.
• New clues about vitamin D functions in the nervous system.Trends Endocrinol Metab. 2002 Apr;13(3):100–5. Review.
• Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.Treat Endocrinol. 2002;1(5):313–27. Review.
• Vitamin D analogues for secondary hyperparathyroidism.Nephrol Dial Transplant. 2002;17 Suppl 10:10–9. Review.
• Vitamin D analogs for the treatment of secondary hyperparathyroidism.Blood Purif. 2002;20(1):109–12. Review.
• Vitamin D analogues for the management of secondary hyperparathyroidism.Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34–40. Review.
• Cancer chemoprevention using natural vitamin D and synthetic analogs.Annu Rev Pharmacol Toxicol. 2001;41:421–42. Review.
• Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post‑menopausal osteoporosis.Cochrane Database Syst Rev. 2001;(1):CD000227. Review.
• Prevention of N‑methyl‑N‑nitrosourea‑induced mammary carcinogenesis in rats by 1alpha‑hydroxyvitamin D(5).J Natl Cancer Inst. 2000 Nov 15;92(22):1836–40.
• Prevention of vitamin D deficiency in adolescents and pre‑adolescents. An interventional multicenter study on the biological effect of repeated doses of 100,000 IU of vitamin D3.Arch Pediatr. 2000 Feb;7(2):148–53. In French.
• Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post‑menopausal osteoporosis.Cochrane Database Syst Rev. 2000;(2):CD000227. Review.
• Treatment of glucocorticoid‑induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.Calcif Tissue Int. 1999 Oct;65(4):337–40.
• Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin  D analog (D‑hormone) therapy.Calcif Tissue Int. 1999 Oct;65(4):295–306. Review.
• Vitamin D analogs: perspectives for treatment.Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
• Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men.Osteoporos Int. 1998;8(3):222–30.
• New 1alpha,25‑dihydroxy‑19‑norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2‑hydroxymethyl, 2‑methyl, and 2‑methylene analogues.J Med Chem. 1998 Nov 5;41(23):4662–74.
• Evidence that vitamin D3 increases serum 25‑hydroxy vitamin D more efficiently than does vitamin D2.Am J Clin Nutr. 1998 Oct;68(4):854–8.
• 19‑Nor‑1‑alpha‑25‑dihydroxy vitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.J Am Soc Nephrol. 1998 Aug;9(8):1427–32.
• Vitamin D3 analogs and their 24‑oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.J Cell Biochem. 1997 Sep 1;66(3):413–25.
• Inhibition of proliferation of prostate cancer cells by a 19‑nor‑hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E‑cadherin.J Mol Endocrinol. 1997 Aug;19(1):15–27.
• Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha‑hydroxyvitamin D5.J Natl Cancer Inst. 1997 Feb 5;89(3):212–8.
• Fortified milk and supplements of oral vitamin D. Comparison of the effect of two doses of vitamin D (500 and 1,000 UI/d) during the first trimester of life.Arch Pediatr. 1997 Feb;4(2):126–32. In French.
• Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.CMAJ. 1996 Oct 1;155(7):955–61. Review.
• Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients.J Am Soc Nephrol. 1996 Mar;7(3):488–96.
• Characterization of a vitamin D3‑resistant MCF‑7 cell line.Endocrinology. 1996 Feb;137(2):400–9.
• Effect of three levels of vitamin D intake in preterm infants receiving high mineral‑containing milk.J Pediatr Gastroenterol Nutr. 1995 Aug;21(2):182–9.
• Vitamin D and pubertal maturation. Value and tolerance of vitamin D supplementation during the winter season.Arch Pediatr. 1995 Mar;2(3):221–6. In French.
• Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25‑dihydroxyvitamin D3.Endocrinology. 1995 Jan;136(1):20–6.
• Selective biological response by target organs (intestine, kidney, and bone) to 1,25‑dihydroxyvitamin D3 and two analogues.Cancer Res. 1993 Sep 1;53(17):3935–42.
• Mineral and vitamin D adequacy in infants fed human milk or formula between 6 and 12 months of age.J Pediatr. 1990 Aug;117(2 Pt 2):S134–42. Review.
• Synthesis and biological activity of novel vitamin D analogues: 24,24‑difluoro‑25‑hydroxy‑26,27‑dimethylvitamin D3 and 24,24‑difluoro‑1 alpha,25‑dihydroxy‑26,27‑dimethylvitamin D3.J Med Chem. 1990 Feb;33(2):480–90.
• Effects of ergocalciferol supplementation on the concentration of vitamin D and its metabolites in human milk.J Nutr. 1989 Nov;119(11):1639–46.
• The difference of biological activity among four diastereoisomers of 1 alpha,25‑dihydroxycholecalciferol‑26,23‑lactone.J Steroid Biochem. 1986 Oct;25(4):505–10.
• 1,25‑Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei.Endocrinology. 1986 Apr;118(4):1433–9.
• Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes.Am J Clin Nutr. 1985 Oct;42(4):644–9.
• Long‑term treatment of postmenopausal osteoporosis with active vitamin D3, 1‑alpha‑hydroxycholecalciferol (1 alpha‑OHD3) and 1,24 Dihydroxycholecalciferol (1,24(OH)2D3).Endocrinol Jpn. 1985 Apr;32(2):305–15.
• 26,26,26,27,27,27‑hexafluoro‑1,25‑dihydroxyvitamin D3: a highly potent, long‑lasting analog of 1,25‑dihydroxyvitamin D3.Arch Biochem Biophys. 1984 Feb 15;229(1):348–54.
• Serum dihydroxyvitamin D metabolite concentrations in patients on chronic anticonvulsant drug therapy: response to pharmacologic doses of vitamin D2.Metab Bone Dis Relat Res. 1983–1984;5(1):1–6.
• Metabolism and binding properties of 24,24‑difluoro‑25‑hydroxyvitamin D3.Arch Biochem Biophys. 1983 Sep;225(2):649–55.
• Variation of 25‑hydroxyvitamin D3 and 25‑hydroxyvitamin D2 levels in human plasma obtained from 758 Japanese healthy subjects.J Nutr Sci Vitaminol (Tokyo). 1983 Jun;29(3):271–81.
• 23‑Keto‑25‑hydroxyvitamin D3: a vitamin D3 metabolite with high affinity for the 1,25‑dihydroxyvitamin D specific cytosol receptor.Biochemistry. 1983 Jan 18;22(2):245–50.
• Vitamin D metabolism in hypoparathyroidism.J Clin Endocrinol Metab. 1980 Sep;51(3):606–10.
• Radioligand receptor assay for 25‑hydroxyvitamin D2/D3 and 1 alpha, 25‑dihydroxyvitamin D2/D3.J Clin Invest. 1976 Jul;58(1):61–70.
• Vitamin D: the discovery of its metabolites and their therapeutic applications.Pediatrics. 1976 May;57(5):729–41. Review.
• The kidney as an endocrine organ involved in the function of vitamin D.Am J Med. 1975 Jan;58(1):39–47. Review.
• Gas chromatographic determination of vitamin D in cod liver oil, pharmaceuticals and veterinary preparations.Int J Vitam Nutr Res. 1973;43(3):271–82.

back to research menu